Page last updated: 2024-10-31

midodrine and Dizziness

midodrine has been researched along with Dizziness in 9 studies

Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.

Dizziness: An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.

Research Excerpts

ExcerptRelevanceReference
"We assessed the potency of octreotide and midodrine, and their combination, in the treatment of the postural tachycardia syndrome (POTS) and orthostatic intolerance (OI)."9.12Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine. ( Bryner, KD; Hobbs, G; Hoeldtke, ME; Hoeldtke, RD, 2006)
"Other than scalp paresthesia in one patient, no adverse effects were noted."5.30Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients? ( Cruz, DN; Mahnensmith, RL; Perazella, MA, 1997)
"We assessed the potency of octreotide and midodrine, and their combination, in the treatment of the postural tachycardia syndrome (POTS) and orthostatic intolerance (OI)."5.12Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine. ( Bryner, KD; Hobbs, G; Hoeldtke, ME; Hoeldtke, RD, 2006)
"A total of 171 patients with orthostatic hypotension participated in a multicenter, randomized, placebo-controlled study."2.68Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. ( Freeman, R; Gilden, JL; Low, PA; McElligott, MA; Sheng, KN, 1997)
"Orthostatic hypotension is defined as a decrease in blood pressure of 20 mm Hg or more systolic or 10 mm Hg or more diastolic within three minutes of standing from the supine position or on assuming a head-up position of at least 60 degrees during tilt table testing."1.72Orthostatic Hypotension: A Practical Approach. ( Farrell, J; Kim, MJ, 2022)
"In case of orthostatic hypotension with an insufficient increase in heart rate, one has to consider autonomic dysfunction."1.72[Dizziness upon standing: consider autonomic dysfunction]. ( Bloem, BR; Deinum, J; Riksen, NP; Rutten, J, 2022)
"Other than scalp paresthesia in one patient, no adverse effects were noted."1.30Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients? ( Cruz, DN; Mahnensmith, RL; Perazella, MA, 1997)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19901 (11.11)18.7374
1990's3 (33.33)18.2507
2000's1 (11.11)29.6817
2010's2 (22.22)24.3611
2020's2 (22.22)2.80

Authors

AuthorsStudies
Kim, MJ1
Farrell, J1
Riksen, NP1
Rutten, J1
Bloem, BR1
Deinum, J1
Tanabe, N1
Takane, K1
Yokoyama, K1
Tanno, Y1
Yamamoto, I1
Ohkido, I1
Yokoo, T1
Wecht, JM1
Radulovic, M1
Rosado-Rivera, D1
Zhang, RL1
LaFountaine, MF1
Bauman, WA1
Hoeldtke, RD1
Bryner, KD1
Hoeldtke, ME1
Hobbs, G1
Low, PA2
Gilden, JL2
Freeman, R2
Sheng, KN2
McElligott, MA2
Cruz, DN1
Mahnensmith, RL1
Perazella, MA1
Sütsch, G1
Vetter, W1
Hess, OM1
Rhyner, K1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevention of Low Blood Pressure in Persons With Tetraplegia[NCT00237770]Phase 2/Phase 316 participants (Actual)Interventional2003-06-30Completed
Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury[NCT03602014]Phase 422 participants (Actual)Interventional2018-06-01Completed
A Dose Response Trial Using 5 and 10 mg. of Midodrine Hydrochloride to Treat Orthostatic Hypotension in Persons With SCI[NCT00426842]Phase 211 participants (Actual)Interventional2007-01-31Completed
Safety and Efficacy of L-NAME and Midodrine to Increase MAP in Persons With Tetraplegia[NCT00835224]Phase 234 participants (Actual)Interventional2010-05-31Completed
Clinical Laboratory Evaluation of Primary Chronic Autonomic Failure[NCT00059033]325 participants (Actual)Observational2003-04-10Terminated
Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study[NCT02308124]Phase 487 participants (Actual)Interventional2014-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Systolic Blood Pressure During Head-up Tilt

Average systolic blood pressure over 45 minutes at 45 degrees of head-up tilt. (NCT00237770)
Timeframe: Average systolic blood pressure during head-up tilt (45 degrees) comparing active drug (L-NAME: 1.0 and 2.0 mg/kg) to placebo.

InterventionmmHg (Mean)
Tetraplegic Systolic Blood Pressure Responses to Placebo91.80
Control Systolic Blood Pressure Responses to Placebo108.10
Tetraplegic Systolic Blood Pressure Responses to L-NAME 1.0 mg112.04
Tetraplegic Systolic Blood Pressure Responses to L-NAME 2.0 mg129.94

Systolic Blood Pressure

brachial artery systolic blood pressure (mmHg) (NCT00426842)
Timeframe: The difference between the average supine systolic blood pressure and the average systolic blood pressure at 45 degree head-up tilt position.

,,
InterventionmmHg (Mean)
Baseline Blood PressureHead-up Tilt Blood Pressure
Midodrine 10 mg102109
Midodrine 5 mg9796
No-drug9887

Blood Pressure

(NCT00835224)
Timeframe: Blood pressure during the 4 hour period after no drug, L-NAME (IV: 1.0 mg/kg) and midodrine (PO: 10.0 mg) administration

InterventionmmHg (Mean)
Arm 1A120
Arm 1B112
Arm 2A117
Arm 2B109
Arm 3A96
Arm 3B109

Change of the Depression Score (Beck Depression Inventory-II )

"Change of the depression score after 3-month medical treatment compared to initial results.~21 multiple-choice questions, each of which can be scored from 0 to 3. Higher score represent higher degree of depression.~Score Normal; 0-13, Mild depression; 14-19, Moderate depression; 20-28, Severe depression; 29-63" (NCT02308124)
Timeframe: after 3-month medical treatment.

Interventionpoints (Mean)
Midodrine Only-6.8
Pyridostigmine Only-7.8
Midodrine + Pyridostigmine-3.5

Change of the Orthostatic Hypotension Associated Symptom Questionnaire (OH Questionnaire (OHQ)).

"Change of the OH associated symptom survey result after 3-month medical treatment compared to initial results.~OHQ questionnaire has two components: the OH daily activity scale (OHDAS), which contains 4 items measuring the impact of OH on daily activities, and the OH symptom assessment (OHSA), which contains 6 items measuring the symptoms of OH (dizziness/light headedness, vision disturbance, weakness, fatigue, trouble concentrating, and head/neck discomfort).This questionnaire reflects the severity of OH-related symptoms on a 10-point scale, with 0 indicating the absence of a symptom and 10 indicating maximal severity.~** OHQ total score minimal 0 ~ maximal 100" (NCT02308124)
Timeframe: after 3-month medical treatment.

Interventionpoints (Mean)
Midodrine Only-16.2
Pyridostigmine Only-17.2
Midodrine + Pyridostigmine-12.6

Changes in Health-related Quality of Life

"changes in Short Form (36) Health Survey version 2 (SF-36v2) mental component summary scale (MCS)~SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores." (NCT02308124)
Timeframe: changes at 3 months after treatment

Interventionpoints (Mean)
Midodrine Only5.0
Pyridostigmine Only6.7
Midodrine + Pyridostigmine0.4

Short-form 36 Version 2

"changes in Short Form (36) Health Survey version 2 (SF-36v2) physical component summary scale (PCS) compared to the baseline~SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores." (NCT02308124)
Timeframe: changes at 3 months after treatment

Interventionpoints (Mean)
Midodrine Only5.6
Pyridostigmine Only4.2
Midodrine + Pyridostigmine2.7

Change in Orthostatic BP Drop

Change of orthostatic SBP and DBP drop after 3-month medical treatment compared to initial results. (NCT02308124)
Timeframe: after 3-month medical treatment

,,
InterventionmmHg (Mean)
Changes in SBP dropChanges in DBP drop
Midodrine + Pyridostigmine8.97.4
Midodrine Only11.17.5
Pyridostigmine Only13.611.1

Trials

2 trials available for midodrine and Dizziness

ArticleYear
Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2006, Volume: 16, Issue:6

    Topics: Adult; Blood Pressure; Data Interpretation, Statistical; Dizziness; Drug Therapy, Combination; Femal

2006
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
    JAMA, 1997, Apr-02, Volume: 277, Issue:13

    Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind

1997
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
    JAMA, 1997, Apr-02, Volume: 277, Issue:13

    Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind

1997
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
    JAMA, 1997, Apr-02, Volume: 277, Issue:13

    Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind

1997
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
    JAMA, 1997, Apr-02, Volume: 277, Issue:13

    Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind

1997

Other Studies

7 other studies available for midodrine and Dizziness

ArticleYear
Orthostatic Hypotension: A Practical Approach.
    American family physician, 2022, 01-01, Volume: 105, Issue:1

    Topics: Accidental Falls; Adolescent; Adult; Aged; Blood Pressure; Chest Pain; Diabetes Mellitus; Diet; Dizz

2022
[Dizziness upon standing: consider autonomic dysfunction].
    Nederlands tijdschrift voor geneeskunde, 2022, 04-25, Volume: 166

    Topics: Aged; Autonomic Nervous System Diseases; Blood Pressure; Dizziness; Humans; Hypotension, Orthostatic

2022
Dialysate temperature adjustment as an effective treatment for baroreflex failure syndrome in hemodialysis patient.
    BMC nephrology, 2014, Sep-17, Volume: 15

    Topics: Aged; Baroreflex; Carotid Sinus; Cold Temperature; Dialysis Solutions; Dizziness; Droxidopa; Enteral

2014
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
    Archives of physical medicine and rehabilitation, 2011, Volume: 92, Issue:11

    Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido

2011
Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients?
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1997, Volume: 30, Issue:6

    Topics: Administration, Oral; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Blood Pressure; Diastole;

1997
Efficacy of midodrine for neurogenic orthostatic hypotension. Reply.
    JAMA, 1997, Aug-06, Volume: 278, Issue:5

    Topics: Adrenergic alpha-Agonists; Dizziness; Humans; Hypotension, Orthostatic; Midodrine; Vasoconstrictor A

1997
[Dizziness, syncope, orthostatic hypotension].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1988, Nov-29, Volume: 77, Issue:48

    Topics: Aged; Dizziness; Epinephrine; Female; Humans; Hypotension, Orthostatic; Midodrine; Norepinephrine; S

1988